BiotechTube

ANB032 + Placebo

Phase 2Terminated
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atopic Dermatitis Eczema

Conditions

Atopic Dermatitis Eczema

Trial Timeline

Jun 13, 2023 → Jan 7, 2025

NCT ID
NCT05935085

About ANB032 + Placebo

ANB032 + Placebo is a phase 2 stage product being developed by AnaptysBio for Atopic Dermatitis Eczema. The current trial status is terminated. This product is registered under clinical trial identifier NCT05935085. Target conditions include Atopic Dermatitis Eczema.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05935085Phase 2Terminated

Competing Products

20 competing products in Atopic Dermatitis Eczema

See all competitors
ProductCompanyStageHype Score
LebrikizumabEli LillyPhase 3
77
Baricitinib + Placebo + Topical corticosteroidEli LillyPhase 3
77
LebrikizumabEli LillyApproved
85
LebrikizumabEli LillyPhase 3
77
Lebrikizumab + PlaceboEli LillyPhase 3
77
BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + GentamicinHoth TherapeuticsPhase 1
25
LebrikizumabEli LillyPhase 3
77
ASN008Formation BioPhase 2
44
ENS-002Concerto BiosciencesPhase 1
25
nemolizumab (CIM331)Chugai PharmaceuticalPhase 2
52
YH35324 + Placebo + OmalizumabYuhanPhase 1
33
YH35324 + Placebo + OmalizumabYuhanPhase 1
33
DS-2741a + PlaceboDaiichi SankyoPhase 1
33
SUN13834 + PlaceboDaiichi SankyoPhase 2
52
5 mg ASB17061 + Placebo + 10 mg ASB17061 + 20 mg ASB17061Daiichi SankyoPhase 2
52
Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%Astellas PharmaPhase 2
52
tacrolimus ointmentAstellas PharmaPhase 3
77
tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
85
tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
85
tacrolimus ointment 0.03% + hydrocortisone acetate ointment 1% + hydrocortisone butyrate ointment 0.1% + Meningitec + AC VAXAstellas PharmaPhase 2
52

Other Products from AnaptysBio

Rosnilimab + PlaceboPhase 2
47
Rosnilimab + PlaceboPhase 2
47
Etokimab + Placebo + Mometasone Furoate Nasal SprayPhase 2
47
Rosnilimab + PlaceboPhase 2
47
Etokimab + PlaceboPhase 2
47